🔗 Share this article

As America undertakes unprecedented adjustments to its immunization recommendations, an unexpected name has emerged in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by casting doubt on Covid vaccinations during the global health crisis and has focused upon possible deaths following COVID-19 vaccination in her short position at the FDA.

Scheduled Shifts to Childhood Immunization Program

Agency leaders planned to announce radical changes to the childhood vaccine schedule recently, synchronizing the US with Denmark’s vaccine program, sources say – a major change that would place the US out of step with much of the world with no evidence for improved outcomes. The announcement has been pushed back until the coming year.

Instead of Vinay Prasad, Tracy Beth Høeg is listed to address the audience at the event. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth appointee to head the office this calendar year.

A New Direction at the FDA

The acting appointment might represent a tighter collaboration between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a greater focus upon dismantling previously authorized immunizations at the FDA.

Høeg has frequently advocated for ending some pediatric vaccine recommendations in the US in order to be more like Denmark, a country with universal health coverage and a number of inhabitants roughly the population of Wisconsin’s.

So far statements, she has kept her attention on immunizations – usually the domain of Prasad, director of the FDA’s vaccine center – instead of pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has no apparent track record in drug development, oversight or leadership, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the agency head and CBER since March.

“It seems she lacks to have any of the qualifications” for leading the CDER, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in leading a major agency. She has no expertise in industry regulation.”

Former heads of CBER would “grasp regulatory frameworks and the research of medication creation”, noted Janet Woodcock. “Clearly, she lacks the kind of background that prior appointees who headed the center have had.”

CDER has an vast portfolio at the FDA, she stated.

“Many people just focuses on the novel medication approvals, but the generic program clears a multitude of off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and more, and each of these must be supervised,” Woodcock noted. “The thing you overlook, that is precisely what that I always told people is going to bite you.”

Additionally, a substantial administrative component to the position, which manages in excess of 5,000 staff members. “It is a huge administrative position, if you do it right,” she added.

Official Statement and Controversial Policies

Regarding inquiries about Høeg’s fitness for the role and whether this assignment signifies increased cooperation among agency officials on vaccines, a representative stated that the “inquiries rely on incorrect presumptions”.

“Her experience matches the duties of her job,” the representative stated, citing the time Høeg spent counseling the agency head on “medication safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg takes over the agency head's controversial priority voucher program, a contentious rapid therapy clearance system that reportedly troubled her preceding directors. “By what process are these therapies being chosen for this expedited pathway? Who is making the calls?” Howard asked. “There’s a lot of confidentiality occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards more relaxed regulations of pharmaceuticals, aside from vaccines.”

Documented Past Work on Immunizations

Concerning vaccines, Høeg has a more established, if troubling, track record, some experts have noted. She published a study using unverified volunteer-provided data to estimate the incidence of myocarditis after Covid vaccination. She advised the Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to imply COVID-19 vaccinations are riskier than they are.

Among her “policy goals” for the incoming federal leadership included altering rules for new vaccines and discontinuing “unnecessary” immunizations, she stated post-election on a online show. At the agency, Dr. Høeg has allegedly floated the idea of barring teenage boys from obtaining COVID-19 vaccinations.

“She’s an all-around true believer who begins with her conclusions and works backwards to accommodate the data in a very deceptive, untruthful way,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of fellow contrarians, {like|